Core Insights - The company reported a significant increase in revenue for the first half of 2025, amounting to 50.96 million yuan, representing a year-on-year growth of 703.8% [1] - Gross profit reached 29.37 million yuan, showing an impressive year-on-year increase of approximately 1,716% [1] - The net loss narrowed to 75.48 million yuan, a reduction of 78.53% compared to the previous year, with a loss per share of 0.14 yuan [1] Financial Performance - Revenue: 50.96 million yuan, up 703.8% year-on-year [1] - Gross Profit: 29.37 million yuan, up approximately 1,716% year-on-year [1] - Net Loss: 75.48 million yuan, down 78.53% year-on-year [1] - Loss per Share: 0.14 yuan [1] Contributing Factors - The reduction in losses was primarily attributed to decreased R&D expenses, lower administrative costs, an increase in net foreign exchange gains, and a rise in gross profit [1]
科济药业-B(02171)公布中期业绩 净亏损7548.3万元 同比收窄78.53%